Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
RESEARCH TOOLSreports
Dianthus Therapeutics (DNTH) Stock Price & Analysis
283 Followers
DNTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.58 - $33.77
Previous Close$26.56
Volume112.24K
Average Volume (3M)250.06K
Market Cap
$779.52M
Enterprise Value$402.98M
Total Cash (Recent Filing)$377.04M
Total Debt (Recent Filing)$497.00K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.89
Shares Outstanding29,349,469
10 Day Avg. Volume351,708
30 Day Avg. Volume250,064
Standard Deviation0.23
R-Squared0.17
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)4.44
Price to Sales (P/S)857.31
Price to Cash Flow (P/CF)-15.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue461.08
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.90
Forecast
1Y Price Target
$41.00Price Target Upside54.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Dianthus Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $6.58 and its highest was $33.77 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Currently, no data Available
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on May 09, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.438 by -$0.102.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 29,349,468 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.438. Following the earnings report the stock price went down -2.567%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Among the largest hedge funds holding Dianthus Therapeutics’s share is Fairmount Funds Management Llc. It holds Dianthus Therapeutics’s shares valued at 83M.
---
Dianthus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (54.37% Upside)
$41.00 (54.37% Upside)
Blogger Sentiment
Bullish
DNTH Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.87%
12-Months-Change
Fundamentals
Return on Equity
-18.82%
Trailing 12-Months
Asset Growth
358.36%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
---
DNTH Stock 12 Month Forecast
Average Price Target
$41.00
▲(54.37% Upside)
Technical Analysis
RegenXBio
―
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
BioMarin Pharmaceutical
―
Best Analysts Covering DNTH
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+39.70%
assigned a buy rating last month
Copying Laura Chico's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +39.70% per trade.
---